Evaxion A/S
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Evaxion A/S
Biological Products, (No Diagnostic Substances), SIC 2836
Evaxion is a biotechnology company that develops targeted immunotherapies and vaccines for cancers and infectious diseases using its proprietary artificial intelligence platform, AI-Immunology. The platform identifies novel disease targets and predicts immune responses to engineer therapeutic cancer vaccines and prophylactic bacterial and viral treatments. Its clinical and preclinical research programs address conditions such as melanoma, leukemia, gonorrhea, and cytomegalovirus. The company generates value through its internal pipeline assets and strategic research collaborations, serving pharmaceutical companies and healthcare partners through licensing and co-development partnerships.
The company operates its research and development activities through dedicated wet-lab and animal testing facilities, utilizing third-party contract manufacturers for trial drug supply. Evaxion maintains international collaborations, including development agreements with partner organizations across the United States, Africa, and global non-profit foundations. Founded in Denmark, the company conducts its business under Danish law and coordinates global operations from Denmark.
Summary of the business section of Evaxion A/S's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Evaxion A/S
- Founded
- 2008
- Headquarters
- Hoersholm, Denmark
- Address
- Dr Neergaards Vej 5f
- Phone
- (455) 265-6554
- Website
- evaxion.ai
- Employees
- 45, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- G7
- Fiscal year ends
- December 31
- Auditor
- EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark
Stock & identifiers
- Ticker
- EVAX
- Exchange
- Nasdaq
- IPO date
- Feb 5, 2021
- Shares outstanding
- 417M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-5 reverse, Jan 14, 2025; 1-for-10 reverse, Jan 22, 2024
- SEC CIK
- 1828253
- CUSIP
- 29970R303
- ISIN
- US29970R3030
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andreas Holm Mattsson | CAIO Chief AI Officer | 5,524,916 |
| Helen Katrina Tayton-Martin | Chief Executive Officer | 2,286,150 |
| Thomas Frederik Schmidt | Chief Financial Officer | 645,750 |
| Birgitte Rono | Chief Scientific Officer | 36,765 |
| A/S Evaxion | Chief Financial Officer | 1,147,178 |
| Jens Bitsch-Norhave | Director | 2,376 |
| Marianne Soegaard | Director | 3,863,115 |
| Lars Aage Staal Wegner | Director | 129,139 |
| Roberto Prego | Director | 1,171,030 |
| Lars Holtug | Director | 258,029 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 45 full-time equivalent employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 5, 2025 | Name change | Name changed from Evaxion Biotech A/S to Evaxion A/S |
| Feb 5, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 26, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |